Vascular α1A Adrenergic Receptors as a Potential Therapeutic Target for IPAD in Alzheimer’s Disease
by
, and
Miles Frost
1, 
Abby Keable
1, 
Dan Baseley
1,
Amber Sealy
1,
Diana Andreea Zbarcea
1,
Maureen Gatherer
1,
Ho Ming Yuen
1,
Matt MacGregor Sharp
1,
Roy O. Weller
1,
Johannes Attems
2,
Colin Smith
3,
Paul R. Chiarot
4 and
Roxana O. Carare
1,* 1
Faculty of Medicine, University of Southampton, Southampton SO16 6YD, UK
2
Translational and Clinical Research Institute, Newcastle University, Newacstle upon Tyne NE4 5PL, UK
3
Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh EH16 4SB, UK
4
Department of Mechanical Engineering, State University of New York at Binghamton, Binghamton, NY 13902, USA
*
Author to whom correspondence should be addressed.
Pharmaceuticals 2020, 13(9), 261; https://doi.org/10.3390/ph13090261
Submission received: 17 August 2020
/
Revised: 14 September 2020
/
Accepted: 19 September 2020
/
Published: 22 September 2020
(This article belongs to the Special Issue New Drugs and Biologics For Treatment of Central Nervous Dysfunction)
Abstract
Drainage of interstitial fluid from the brain occurs via the intramural periarterial drainage (IPAD) pathways along the basement membranes of cerebral capillaries and arteries against the direction of blood flow into the brain. The cerebrovascular smooth muscle cells (SMCs) provide the motive force for driving IPAD, and their decrease in function may explain the deposition of amyloid-beta as cerebral amyloid angiopathy (CAA), a key feature of Alzheimer’s disease. The α-adrenoceptor subtype α1A is abundant in the brain, but its distribution in the cerebral vessels is unclear. We analysed cultured human cerebrovascular SMCs and young, old and CAA human brains for (a) the presence of α1A receptor and (b) the distribution of the α1A receptor within the cerebral vessels. The α1A receptor was present on the wall of cerebrovascular SMCs. No significant changes were observed in the vascular expression of the α1A-adrenergic receptor in young, old and CAA cases. The pattern of vascular staining appeared less punctate and more diffuse with ageing and CAA. Our results show that the α1A-adrenergic receptor is preserved in cerebral vessels with ageing and in CAA and is expressed on cerebrovascular smooth muscle cells, suggesting that vascular adrenergic receptors may hold potential for therapeutic targeting of IPAD.
1. Introduction
Alzheimer’s disease (AD) is the commonest form of dementia, and a key pathological feature of AD is represented by the accumulation of amyloid-beta (Aβ) within the walls of cortical and leptomeningeal arteries as cerebral amyloid angiopathy (CAA) [1]. The changes observed in early CAA are astrogliosis, combined with a dysregulation in lipid metabolism, and Apolipoprotein E and Triggering receptor expressed on myeloid cells 2 (TREM2) [2]. While in familial CAA there is overproduction of normal or mutated proteins such as Aβ, cystatin C or ABri, in sporadic CAA it is the failure of clearance rather than overproduction of Aβ that is responsible for its accumulation in the ageing brain [3,4]. There are several ways in which Aβ can be cleared, such as transcytosis via lipoprotein-related-protein-1 or phagocytosis by perivascular cells or microglia, but these mechanisms fail with ageing [5]. The role of vascular factors such as small vessel disease has been recently recognized in the pathogenesis of CAA and AD [6]. Apart from the supply of blood, which decreases in early AD through hypoperfusion, the cerebral arteries have another recently recognized function: the drainage of waste and soluble interstitial fluid along their walls [5]. Lymphatic drainage of the brain occurs along the basement membranes of capillaries and arteries, as intramural periarterial drainage (IPAD) [7,8,9]. With increasing age and possession of ApoE ε4 genotype, vascular basement membranes change their composition, thereby reducing the efficiency of IPAD [10,11,12].
Multi-scale modelling of cerebral arteries demonstrates that the motive force generated by cerebrovascular smooth muscle cells (SMCs), termed vasomotion, is the motive force for IPAD, and this has been supported by recent experimental work [13,14,15]. Increased levels of myocardin and serum response factor in blood vessels in CAA may reflect a decrease in the function of SMCs and clearance of Aβ [16,17]. Since the SMCs generate the vasomotion for IPAD, the innervation of cerebrovascular SMCs is an attractive target for improving IPAD and subsequently preventing or ameliorating CAA.
Leptomeningeal vessels are innervated extrinsically by the peripheral nervous system, whereas parenchymal vessels are innervated intrinsically from within the brain, receiving afferents from subcortical neurons of the raphe nucleus, nucleus basalis and locus coeruleus (LC). Noradrenaline mediates smooth muscle contraction within blood vessels via α-adrenergic receptors, otherwise known as α-adrenoceptors (α-ARs) [18]. LC, the main noradrenergic nucleus in the brain, degenerates in early stages of AD [19,20,21]. It is known that SMCs express α-Ars, but the expression of α-ARs specifically on SMCs of the cerebral blood vessels is not well documented [22].
In this human neuropathological study, we characterised the expression of α1A-AR within the human cerebral vasculature of the occipital lobe, a region preferentially affected by CAA and on cultured human brain vascular SMCs. We hypothesised that α1A-AR is preserved in the ageing arteries and in CAA, providing a look to the future for targeting α1A-AR for the prevention and treatment of CAA.
2. Results
2.1. Post-Mortem Delay Does Not Adversely Affect AR Staining
The association between AR expression and post-mortem delay was investigated in grey and white matter. The Pearson’s correlation coefficient showed a positive correlation in the grey matter (n = 15, r = 0.51, p = 0.05) and the white matter (n = 15, r = 0.15, p = 0.6); however, a sensitivity analysis revealed two outliers, and following removal of these outliers, there was only a weak positive correlation observed in the grey and white matter (0.16 and 0.12, respectively), which was not considered statistically significant (p = 0.609 and 0.707 respectively). We concluded that post-mortem delay was therefore unlikely to have a significant impact on the findings reported. As our numbers of cases were low, we included the two outliers in the analysis of the α1A-AR.
2.2. The Overall Pattern of Immunocytochemistry for α1A-AR on the Cerebral Vessels Is Not Affected by Age
We used immunohistochemistry to assess overall α1A-AR expression in grey and white matter in young, old and CAA cases. In all 15 cases, α1A-AR expression was observed within neurons of the parenchyma and the vascular wall in both grey and white matter (Figure 1 and Figure 2).
In both grey and white matter, neuronal staining appeared most intense in young cases and decreased in both old and CAA cases. The CAA cases were all diagnosed with Vonsattel scores 2 (moderate, the tunica media is replaced by amyloid and is thicker than normal) or 3 (severe, extensive amyloid deposition with focal wall fragmentation). Due to the low number of cases, it is not possible to perform correlation with the Vonsattel scores, but all CAA cases were moderate/severe.
In grey matter, analysis of overall percentage area staining revealed a trend towards a decrease in α1A-AR with age and CAA. Overall percentage area stained in young cases was higher than in old cases (3.56% vs. 2.48% p = 0.305) and significantly higher than in CAA cases (3.56% vs. 1.68% p = 0.029). Overall percentage area stained in old cases was higher but not significantly different from CAA cases (2.48% vs. 1.68% p = 0.658) (Figure 1 and Table 1). In white matter, analysis of overall percentage area staining was highest in young cases but not considered statistically significant when compared to old (1.47% vs. 0.79% p = 0.113) or CAA cases (1.47% vs. 0.91% p = 0.223). There was no significant difference between old and CAA cases (0.79% vs. 0.91%) and no difference between leptomeningeal arteries from young, old and CAA (Figure 2 and Figure 3 and Table 1).
2.3. Vascular α1A-AR Expression Is Unaltered with Age and Disease in the Occipital Lobe
The immunocytochemical expression of α1A-AR was observed within the vascular wall in vessels of the grey matter, white matter and the leptomeninges. Vascular staining appeared punctate and dispersed neatly throughout the vessel wall in young cases. This pattern was not observed in the old and CAA cases, where the staining appeared more diffuse (Figure 3). Despite the differences in the appearance of staining, there were no significant differences observed in the percentage area of the vessel wall stained for α1A-AR in any of the regions of interest (Table 1). Representative images of α1A-AR and amyloid-beta double staining in CAA cases showed α1A-AR expression in vessels with a high amyloid load (Figure 4).
2.4. α1A-AR Co-Localises with Endothelial and Smooth Muscle Cell Markers in Capillaries, Arteries and Veins and with Cultured Vascular Smooth Muscle Cells
Capillaries, arteries and veins all showed expression of α1A-AR in the vascular wall in all regions analysed. In the arterial wall, double immunofluorescence revealed a strong co-localisation of α1A-AR with smooth muscle actin and to a lesser degree with lectin (Figure 5). A similar co-localisation of α1A-AR with lectin was also observed in the vessel walls of capillaries and veins. In cultured human brain vascular smooth muscle cells (HBVSMC), staining for α1A-AR appeared to outline the smooth muscle cell body (Figure 5).
3. Discussion
This study has shown the qualitative and quantitative differences in the expression of the α1A-AR in the grey and white matter of the occipital lobe from young, old and CAA brains. It has also demonstrated that while there is a decrease in overall α1A-AR expression in the grey matter of CAA cases, the vascular expression remains relatively unchanged and the α1A-AR was still detected in the walls of vessels laden with Aβ.
Changes in AR expression have been previously reported in brain regions affected by AD pathology such as increases in the prefrontal cortex, hippocampus and amygdala. This suggests a compensatory mechanism to overcome a decrease in noradrenergic input due to the degeneration of the locus coeruleus seen in early stages of AD [19,23]. We did not observe any significant quantitative changes to α1A-AR expression within the vessels. However, the change in appearance of expression from punctate in young brains to diffuse in old and CAA brains may suggest a redistribution of the α1A-AR on the blood vessels, likely resulting in functional vasomotor deficit. This would be particularly relevant to the accumulation of protein deposits in the vessel wall as CAA caused by a reduced efficiency of IPAD, a process that most likely relies upon adrenergic innervation [13].
Preservation of vascular α1A-ARs shown in this study highlights their potential as possible therapeutic targets for IPAD in AD, and this requires experimental in vivo testing. Prazosin, the only clinically available α1-AR antagonist that can cross the blood–brain barrier has been shown to induce an anti-inflammatory response in the brain, preventing memory deficits over time in mutant transgenic APP23 mice [24]. Furthermore, administration of Prazosin improved behavioural symptoms in patients with agitation/aggression in AD [25]. It remains to be seen whether the effects of Prazosin are mediated by vascular α1A-ARs. The morphological relationship between α1A-AR immunostaining and Aβ would be a useful exercise in a future in vivo experimental study where we would administer α1A-AR antagonist such as Prazosin to test whether it alleviates the pathological features of CAA. Prazosin for Disruptive Agitation in Alzheimer’s Disease (PEACE-AD) is a Phase IIb multicenter, randomized, double-blind, placebo-controlled trial of 12-weeks treatment with Prazosin in Alzheimer’s disease, due to end on 31 December 2021 (NCT03710642), and this may reveal evidence for the prevention of CAA or brain haemorrhages.
The synergistic effects of the other receptors may have profound implications on the pathogenesis of AD and CAA. For example, the vasoconstriction generated by agonists of the α1A-ARs is enhanced by stimulation of the apelin receptor [26]. Genetic deficiency of the α2A-AR significantly reduces Aβ generation, whereas stimulation of this receptor enhances it [27]. Recent studies also demonstrate that Aβ oligomers bind to the α2A-AR, leading to glycogen synthase kinase 3β (GSK3β) hyperphosphorylation of tau [28].
There are limitations to this study, as it is a simple neuropathological assessment of the pattern of distribution of α1A-ARs in the vasculature of young, old non-demented and CAA cases, using a small sample size. However, the present study paves the way for experimental targeting of adrenergic receptors for the prevention and treatment of CAA, as we show they are still present in aged and CAA vessels. Further experimental studies testing the effect of adrenergic antagonists on vascular SMCs possibly used in combination with treatments that alter cholinergic innervation will act upon IPAD pathways for the prevention and treatment of CAA and AD.
4. Materials and Methods
4.1. Brain Tissue Cohort
Sections of 10 μm thickness of post-mortem human occipital cortex were used in this study. Human tissue from young post-mortem donors (≤60 years old) was supplied by the Medical Research Council-funded Edinburgh Sudden Death Tissue Brain Bank (Ethics REC 16/ES/0084). Tissue from old (≥65 years old) and CAA-affected post-mortem donors was supplied by the Newcastle Brain Tissue Resource (Ethics REC 08/H0906/136 + 5). The demographics of the cases used are summarised in Table 2. The cases from the MRC Sudden Death Brain and Tissue Bank (Edinburgh) had no neurological disease during life and no significant neuropathological changes postmortem. CAA cases were diagnosed post-mortem by JA, and Vonsattel scores are included in Table 2.
4.2. Cell Culture
Human brain vascular smooth muscle cells (HBVSMC) were obtained from Sciencell (sc-1100). Cells were maintained in a humidified atmosphere of 5% CO2 and 95% air at 37 °C in a smooth muscle basal medium (sc-1101b) supplemented with smooth muscle cell growth supplement (sc-1152), 100 U/mL penicillin, 100 μg/mL streptomycin (sc-0503) and 2% foetal bovine serum (sc-0010). The medium was refreshed every 2–3 days according to the manufacturer’s instructions. Cells were plated onto poly-L-lysine coated coverslips in a 24-well plate at a seeding density of 0.05 × 106 cells per coverslip.
4.3. Immunohistochemistry on Human Tissue
Sections were deparaffinised and rehydrated through xylene and a graded series of alcohols. Endogenous peroxidase activity was quenched with 3% hydrogen peroxide for 15 min. Sections were washed three times with phosphate-buffered saline (PBS). Heat-induced antigen retrieval was then performed by microwaving in citrate buffer (10 mM, pH 6) for 25 min. Sections were incubated in a blocking solution containing 15% normal goat serum (Sigma, G9023) diluted in phosphate-buffered saline with 0.1% triton X-100 (PBSt) for 1 h prior to overnight incubation at 4 °C with anti α1A-AR primary antibody (rabbit polyclonal, 1:200, Protein Tech, 19777-1-AP) diluted in PBSt. After washing with PBS, sections were incubated for 1 h with a biotinylated goat anti-rabbit secondary antibody (Vector BA-1000). Sections were washed with PBS and incubated with Vectastain Avidin-biotin complex (Vector PK-4000) for 1 h. Sections were rinsed with 0.1M sodium acetate buffer, then incubated with glucose oxidase diaminobenzidine nickel solution for 7 min. Finally, sections were rinsed with 0.1M sodium acetate buffer, followed by PBS before dehydration through graded alcohols and xylene and mounted with DPX. Care was taken in the selection of primary antibody to ensure thorough validation had been carried out to confirm specificity. Validation of Proteintech 19777-1-AP comprised of (1) Western blot of 3 different whole-cell lysates to show a single band at expected molecular weight; (2) peptide blocking, which eliminated the antibody reactivity and (3) short hairpin (sh)RNA knockdown in transfected HeLa cells, which showed a marked reduction in α1A-AR. These validation methods align with the published recommendations for assessment of specificity of antibodies [29].
4.4. Immunofluorescence on Human Tissue
Vascular α1A-AR expression was assessed in all cases using immunofluorescence and confocal microscopy. We first investigated α1A-AR expression with vessel type (capillaries, arteries or veins) and then cell-specific expression using markers for endothelium and smooth muscle cells. Sections were deparaffinised and rehydrated through xylene and a graded series of alcohols to PBS. Antigen retrieval was performed by microwaving in citrate buffer (10 mM, pH 6) for 25 min. After washing with PBS, sections were incubated in pepsin (1 mg/mL dissolved in 0.2 M HCL) at 37 °C for 3 min. Sections were washed three times with PBS and blocked with 15% normal goat serum diluted with PBSt for 1 h. Sections were incubated overnight with anti-SMA (mouse monoclonal, 1:200, Millipore), anti-α1A-AR (Rabbit polyclonal, 1:200, ProteinTech 19777-1-AP) and Dylight 647 tagged endothelium marker; Lycopersicon Esculentum (Tomato) lectin (1:100, Vector DL1178) at 4 °C. After washing with PBS, sections were incubated with biotinylated goat anti-rabbit (1:200, Vector) and goat anti-mouse AlexaFluor 594 conjugated (1:200, ThemoFisher A11032) secondary antibodies for 1 h at room temperature. Sections were washed again with PBS before incubation with streptavidin 488 (Vector) for 1 h at room temperature. Slides were washed with PBS and incubated with Sudan Black (Sigma-Aldrich, 1% in 70% alcohol) for 3 min to quench autofluorescence. Sections were rinsed with PBS and mounted with Mowiol (Sigma-Aldrich).
In order to ascertain whether α1A-AR were preserved in vessels exhibiting Aβ deposition in the vessel wall (CAA), double immunostaining for α1A-AR and Aβ was performed on the cases with CAA. Sections were deparaffinised and rehydrated through a graded series of alcohols. Sections were washed three times with tris-buffered saline (TBS) and incubated in 98% formic acid for 1 min at room temperature. Antigen retrieval was performed by microwaving in citrate buffer for 25 min. After washing with TBS, sections were first incubated in pepsin (1 mg/mL dissolved in 0.2 M HCL) at 37 °C for 3 min and then in a blocking solution consisting of TBS with 0.1% Triton and 15% normal goat serum (Sigma) for 1 h prior to incubation with primary antibodies. Sections were incubated overnight with anti-amyloid beta (mouse monoclonal isotype IgG2b, 1:100, (Biolegend SIG-39220)) and anti-α1A (rabbit polyclonal, 1:200, (ProteinTech 19777-1-AP)) at 4 °C. After washing with TBS, sections were incubated in secondary antibodies comprising Alexa fluor 647 goat anti-mouse IgG2b (1:200, Invitrogen A-21242) and Alexa Fluor 555 goat anti-rabbit (1:200 Invitrogen A-21429) for 1 h at room temperature. Slides were washed in TBS and incubated with Sudan Black (Sigma-Aldrich, 1% in 70% alcohol) for 3 min to quench autofluorescence before being washed in TBS and coverslipped with Mowiol (Sigma-Aldrich).
4.5. Immunofluorescence on Cell Cultures
After 72 h in culture, cells were fixed with 4% paraformaldehyde for 10 min at room temperature, rinsed thoroughly with PBS and then blocked with 15% normal goat serum diluted in PBSt for 1 h before overnight incubation with anti-α1A-AR (Rabbit polyclonal, 1:200, ProteinTech 19777-1-AP) primary antibody. Cells were further rinsed with PBS before incubation with goat anti-rabbit Alexa Fluor 488 conjugated secondary antibody (Invitrogen, A-11034) for 1 h, followed by incubation in 2 µg/mL 4′,6-diamidino-2-phenylindole (DAPI) (Thermo Fisher, D1306) for 10 min. Cells were rinsed with PBS, and then coverslips were carefully removed from the 24-well plate and mounted onto slides with Mowiol and CitiFluor.
4.6. Imaging
The DAB-stained occipital lobe sections were imaged with an Olympus dot slide microscope. Using the tissue microarray function, ten adjacent non-overlapping images of 0.5 mm2 were obtained from the grey matter and the underlying white matter of each case using the 10× objective. Blood vessels that were observed in the grey matter, white matter and leptomeninges were imaged with the 20× objective. To prevent selection bias, the first five blood vessels observed in each region of interest were imaged, regardless of size, shape or plane. Representative images from the immunofluorescence staining were captured using a Leica TCS SP8 laser scanning confocal microscope.
4.7. Image Analysis and Statistics
The images obtained from the Olympus dot slide were used to quantify the expression of α1A-AR in the human brain sections. The percentage area stained for each image was calculated using an automated macro created using the ImageJ software, and an average was calculated from the values obtained from the ten images. To calculate the percentage area of staining in the vessel wall, ImageJ software was used to draw around the vessel, and the area stained was divided by the total area to give a percentage staining in the vessel wall. Where a transverse section of a blood vessel was captured, the lumen area was subtracted from the total area before dividing by the area stained. An average was obtained from the five vessels per region per case. Data were exported to SPSS software version 25 for statistical analysis. A Pearson’s bivariate correlation analysis was carried out to assess the relationship between adrenergic receptor staining and post mortem delay. A sensitivity test was also performed to investigate potential outliers. Percentage area stained data were analysed using a one way ANOVA with Bonferroni post hoc correction for multiple comparisons. Data are presented as mean ±95% confidence intervals with differences considered significant if p < 0.05.
Author Contributions
M.F., A.S. and D.A.Z. performed immunohistochemistry, immunofluorescence, imaging, ImageJ and statistical analysis. M.G. assisted with the immunohistochemistry, immunofluorescence and imaging. A.K. and D.B. assisted with cell culture. H.M.Y. performed statistical analysis. R.O.W. and P.R.C. advised on the study. J.A. diagnosed the CAA. cases and C.S. diagnosed the control cases. M.M.S. assisted with the analysis. R.O.C. designed and advised on the study. All authors have read and agreed to the published version of the manuscript.
Funding
This work was supported and funded by the Anatomical Society, British Neuropathological Society, the Pathological Society of GB and National Institutes of Health award 5R21AG052860-02. Work on the CFAS neuropathology cohort is supported by a grant from the Alzheimer’s Society to SBW and JES (AS-PG-14-015). Work in the individual CFAS centres is supported by the UK NIHR Biomedical Research Centre for Ageing and Age—awarded to Newcastle-upon-Tyne Hospitals Foundation Trust; Cambridge Brain Bank supported by the NIHR Cambridge Biomedical Research Centre; Nottingham University Hospitals NHS Trust; University of Sheffield, Sheffield Teaching Hospitals NHS Foundation Trust and Sheffield NIHR Biomedical Research Centre; The Thomas Willis Oxford Brain Collection, supported by the Oxford Biomedical Research Centre; The Walton Centre NHS Foundation Trust, Liverpool. Tissue for this study was also provided by the Newcastle Brain Tissue Resource, which is funded in part by a grant from the UK Medical Research Council (G0400074), by Brains for Dementia research, a joint venture between Alzheimer’s Society and Alzheimer’s Research UK and by the NIHR Newcastle Biomedical Research Centre awarded to the Newcastle upon Tyne Hospitals NHS Foundation Trust and Newcastle University.
Acknowledgments
We thank the MRC-funded Edinburgh Sudden Death Tissue Brain Bank and the Newcastle Brain Tissue Resource for providing the material for this study. We would like to acknowledge the essential contribution of the liaison officers, the general practitioners, their staff, and nursing and residential home staff. We are grateful to our respondents and their families for their generous gift to medical research, which has made this study possible.
Conflicts of Interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
References
- Attems, J.; Jellinger, K.; Thal, D.R.; Van Nostrand, W. Review: Sporadic cerebral amyloid angiopathy. Neuropathol. Appl. Neurobiol. 2011, 37, 75–93. [Google Scholar] [CrossRef] [PubMed]
- Taylor, X.; Cisternas, P.; You, Y.; You, Y.; Xiang, S.; Marambio, Y.; Zhang, J.; Vidal, R.; Lasagna-Reeves, C.A. A1 reactive astrocytes and a loss of TREM2 are associated with an early stage of pathology in a mouse model of cerebral amyloid angiopathy. J. Neuroinflamm. 2020, 17, 223. [Google Scholar] [CrossRef]
- Mawuenyega, K.G.; Sigurdson, W.; Ovod, V.; Munsell, L.; Kasten, T.; Morris, J.C.; Yarasheski, K.E.; Bateman, R. Decreased clearance of CNS beta-amyloid in Alzheimer’s disease. Science 2010, 330, 1774. [Google Scholar] [CrossRef] [PubMed]
- Revesz, T.; Ghiso, J.; Lashley, T.; Plant, G.; Rostagno, A.; Frangione, B.; Holton, J.L. Cerebral Amyloid Angiopathies: A Pathologic, Biochemical, and Genetic View. J. Neuropathol. Exp. Neurol. 2003, 62, 885–898. [Google Scholar] [CrossRef] [PubMed]
- Tarasoff-Conway, J.M.; Carare, R.O.; Osorio, R.S.; Glodzik, L.; Butler, T.; Fieremans, E.; Axel, L.; Rusinek, H.; Nicholson, C.; Zlokovic, B.V.; et al. Clearance systems in the brain—Implications for Alzheimer disease. Nat. Rev. Neurol. 2015, 11, 457–470. [Google Scholar] [CrossRef] [PubMed]
- Sweeney, M.D.; Montagne, A.; Sagare, A.P.; Nation, D.A.; Schneider, L.S.; Chui, H.C.; Harrington, M.G.; Pa, J.; Law, M.; Wang, D.J.J.; et al. Vascular dysfunction-The disregarded partner of Alzheimer’s disease. Alzheimer’s Dement. 2019, 15, 158–167. [Google Scholar] [CrossRef]
- Carare, R.O.; Bernardes-Silva, M.; Newman, T.A.; Page, A.M.; Nicoll, J.A.R.; Perry, V.H.; Weller, R.O. Solutes, but not cells, drain from the brain parenchyma along basement membranes of capillaries and arteries: Significance for cerebral amyloid angiopathy and neuroimmunology. Neuropathol. Appl. Neurobiol. 2008, 34, 131–144. [Google Scholar] [CrossRef]
- Morris, A.W.J.; Sharp, M.M.; Albargothy, N.J.; Fernandes, R.; Hawkes, C.A.; Verma, A.; Weller, R.O.; Carare, R.O. Vascular basement membranes as pathways for the passage of fluid into and out of the brain. Acta Neuropathol. 2016, 131, 725–736. [Google Scholar] [CrossRef]
- Albargothy, N.J.; Johnston, D.A.; Sharp, M.M.; Weller, R.O.; Verma, A.; Hawkes, C.A.; Carare, R.O. Convective influx/glymphatic system: Tracers injected into the CSF enter and leave the brain along separate periarterial basement membrane pathways. Acta Neuropathol. 2018, 136, 139–152. [Google Scholar] [CrossRef]
- Hawkes, C.A.; Härtig, W.; Kacza, J.; Schliebs, R.; Weller, R.O.; Nicoll, J.A.; Carare, R.O. Perivascular drainage of solutes is impaired in the ageing mouse brain and in the presence of cerebral amyloid angiopathy. Acta Neuropathol. 2011, 121, 431–443. [Google Scholar] [CrossRef]
- Hawkes, C.A.; Gatherer, M.; Sharp, M.M.; Dorr, A.; Yuen, H.M.; Kalaria, R.; Weller, R.O.; Carare, R.O. Regional differences in the morphological and functional effects of aging on cerebral basement membranes and perivascular drainage of amyloid-β from the mouse brain. Aging Cell 2013, 12, 224–236. [Google Scholar] [CrossRef] [PubMed]
- Hawkes, C.A.; Sullivan, P.M.; Hands, S.; Weller, R.O.; Nicoll, J.A.R.; Carare, R.O. Disruption of Arterial Perivascular Drainage of Amyloid-β from the Brains of Mice Expressing the Human APOE ε4 Allele. PLoS ONE 2012, 7, e41636. [Google Scholar] [CrossRef] [PubMed]
- Aldea, R.; Weller, R.O.; Wilcock, D.M.; Carare, R.O.; Richardson, G. Cerebrovascular Smooth Muscle Cells as the Drivers of Intramural Periarterial Drainage of the Brain. Front. Aging Neurosci. 2019, 11, 1. [Google Scholar] [CrossRef] [PubMed]
- Van Veluw, S.J.; Hou, S.S.; Calvo-Rodriguez, M.; Arbel-Ornath, M.; Snyder, A.C.; Frosch, M.P.; Greenberg, S.M.; Bacskai, B.J. Vasomotion as a Driving Force for Paravascular Clearance in the Awake Mouse Brain. Neuron 2020, 105, 549–561. [Google Scholar] [CrossRef] [PubMed]
- Carare, R.O.; Aldea, R.; Bulters, D.; Alzetani, A.; Birch, A.A.; Richardson, G.; Weller, R.O. Vasomotion Drives Periarterial Drainage of Aβ from the Brain. Neuron 2020, 105, 400–401. [Google Scholar] [CrossRef]
- Bell, R.D.; Deane, R.; Chow, N.; Long, X.; Sagare, A.; Singh, I.; Streb, J.W.; Guo, H.; Rubio, A.; Van Nostrand, W.; et al. SRF and myocardin regulate LRP-mediated amyloid-beta clearance in brain vascular cells. Nat. Cell Biol. 2009, 11, 143–153. [Google Scholar] [CrossRef]
- Bell, R.D.; Zlokovic, B.V. Neurovascular mechanisms and blood-brain barrier disorder in Alzheimer’s disease. Acta Neuropathol. 2009, 118, 103–113. [Google Scholar] [CrossRef]
- Harik, S.I.; Sromek, S.M.; Kalaria, R.N. Alpha- and beta-adrenergic receptors of the rat cerebral cortex and cerebral microvessels in aging, and their response to denervation. Neurobiol. Aging 1991, 12, 567–573. [Google Scholar] [CrossRef]
- Andrés-Benito, P.; Fernández-Dueñas, V.; Carmona, M.; Escobar, L.A.; Torrejón-Escribano, B.; Aso, E.; Ciruela, F.; Ferrer, I. Locus coeruleus at asymptomatic early and middle Braak stages of neurofibrillary tangle pathology. Neuropathol. Appl. Neurobiol. 2017, 43, 373–392. [Google Scholar] [CrossRef]
- Betts, M.J.; Cardenas-Blanco, A.; Kanowski, M.; Spottke, A.; Teipel, S.J.; Kilimann, I.; Jessen, F.; Düzel, E. Locus coeruleus MRI contrast is reduced in Alzheimer’s disease dementia and correlates with CSF Aβ levels. Alzheimer’s Dement. 2019, 11, 281–285. [Google Scholar] [CrossRef]
- Betts, M.J.; Kirilina, E.; Otaduy, M.C.G.; Ivanov, D.; Acosta-Cabronero, J.; Callaghan, M.F.; Lambert, C.; Cardenas-Blanco, A.; Pine, K.; Passamonti, L.; et al. Locus coeruleus imaging as a biomarker for noradrenergic dysfunction in neurodegenerative diseases. Brain 2019, 142, 2558–2571. [Google Scholar] [CrossRef] [PubMed]
- Haase, N.; Herse, F.; Spallek, B.; Haase, H.; Morano, I.; Qadri, F.; Szijártó, I.A.; Rohm, I.; Yilmaz, A.; Warrington, J.P.; et al. Amyloid- Peptides Activate 1-Adrenergic Cardiovascular Receptors. Hypertension 2013, 62, 966–972. [Google Scholar] [CrossRef] [PubMed]
- Szot, P.; White, S.S.; Greenup, J.L.; Leverenz, J.B.; Peskind, E.R.; Raskind, M.A. Changes in adrenoreceptors in the prefrontal cortex of subjects with dementia: Evidence of compensatory changes. Neuroscience 2007, 146, 471–480. [Google Scholar] [CrossRef] [PubMed]
- Katsouri, L.; Vizcaychipi, M.P.; McArthur, S.; Harrison, I.F.; Suárez-Calvet, M.; Lleo, A.; Lloyd, D.G.; Ma, D.; Sastre, M. Prazosin, an α1-adrenoceptor antagonist, prevents memory deterioration in the APP23 transgenic mouse model of Alzheimer’s disease. Neurobiol. Aging 2013, 34, 1105–1115. [Google Scholar] [CrossRef] [PubMed]
- Wang, L.Y.; Shofer, J.B.; Rohde, K.; Hart, K.L.; Hoff, D.J.; McFall, Y.H.; Raskind, M.A.; Peskind, E.R. Prazosin for the Treatment of Behavioral Symptoms in Patients With Alzheimer Disease With Agitation and Aggression. Am. J. Geriatr. Psychiatry 2009, 17, 744–751. [Google Scholar] [CrossRef] [PubMed]
- Nagano, K.; Kwon, C.; Ishida, J.; Hashimoto, T.; Kim, J.-D.; Kishikawa, N.; Murao, M.; Kimura, K.; Kasuya, Y.; Kimura, S.; et al. Cooperative action of APJ and α1A-adrenergic receptor in vascular smooth muscle cells induces vasoconstriction. J. Biochem. 2019, 166, 383–392. [Google Scholar] [CrossRef]
- Chen, Y.; Peng, Y.; Che, P.; Gannon, M.; Liu, Y.; Li, L.; Bu, G.; Van Groen, T.; Jiao, K.; Wang, Q. α2A adrenergic receptor promotes amyloidogenesis through disrupting APP-SorLA interaction. Proc. Natl. Acad. Sci. USA 2014, 111, 17296–17301. [Google Scholar] [CrossRef]
- Zhang, F.; Gannon, M.; Chen, Y.; Yan, S.; Zhang, S.; Feng, W.; Tao, J.; Sha, B.; Liu, Z.; Saito, T.; et al. β-amyloid redirects norepinephrine signaling to activate the pathogenic GSK3β/tau cascade. Sci. Transl. Med. 2020, 12. [Google Scholar] [CrossRef]
- Michel, M.C.; Wieland, T.; Tsujimoto, G. How reliable are G-protein-coupled receptor antibodies? Naunyn Schmiedebergs Arch. Pharmacol. 2009, 379, 385–388. [Google Scholar] [CrossRef]
Figure 1.
The pattern of distribution of the α-adrenoceptors alpha1a adrenergic receptor (α1A-AR) in the grey matter of the occipital lobe. Neuronal staining appeared most intense in young cases (A) and decreased in both old (B) and cerebral amyloid angiopathy (CAA) cases (C). In all cases, α1A-AR immunoreactivity was observed in vessel walls (enlarged boxes 1, 2 and 3). There was a significant decrease in α1A-AR in CAA cases compared to young groups (D) and no differences observed in the vessel wall (E). Graphs depict the mean ±95% confidence intervals; n = 5. Scale bar 50 µm. * p < 0.05.
Figure 1.
The pattern of distribution of the α-adrenoceptors alpha1a adrenergic receptor (α1A-AR) in the grey matter of the occipital lobe. Neuronal staining appeared most intense in young cases (A) and decreased in both old (B) and cerebral amyloid angiopathy (CAA) cases (C). In all cases, α1A-AR immunoreactivity was observed in vessel walls (enlarged boxes 1, 2 and 3). There was a significant decrease in α1A-AR in CAA cases compared to young groups (D) and no differences observed in the vessel wall (E). Graphs depict the mean ±95% confidence intervals; n = 5. Scale bar 50 µm. * p < 0.05.
Figure 2.
The pattern of distribution of the α1A-AR in the white matter of the occipital lobe. Neuronal staining appeared most intense in young cases (A) and appeared to decrease in both old (B) and CAA cases (C). In all cases, α1A-AR immunoreactivity was observed in vessel walls (enlarged boxes 1, 2 and 3). There were no significant differences observed in overall percentage area staining (D) or the percentage of the vessel wall positive for α1A-AR in white matter (E). Graphs depict the mean ±95% confidence intervals, n = 5. Scale bar 50 µm.
Figure 2.
The pattern of distribution of the α1A-AR in the white matter of the occipital lobe. Neuronal staining appeared most intense in young cases (A) and appeared to decrease in both old (B) and CAA cases (C). In all cases, α1A-AR immunoreactivity was observed in vessel walls (enlarged boxes 1, 2 and 3). There were no significant differences observed in overall percentage area staining (D) or the percentage of the vessel wall positive for α1A-AR in white matter (E). Graphs depict the mean ±95% confidence intervals, n = 5. Scale bar 50 µm.
Figure 3.
The pattern of distribution of the α1A-AR in leptomeningeal vessels of the occipital lobe. In all cases, α1A-AR immunoreactivity was observed in vessel walls (A, B and C and enlarged boxes 1, 2 and 3). There were no significant differences in the percentage of the vessel wall positive for α1A-AR between cases (D). Graph depicts the mean ±95% confidence intervals, n = 5. Scale bar 50 µm.
Figure 3.
The pattern of distribution of the α1A-AR in leptomeningeal vessels of the occipital lobe. In all cases, α1A-AR immunoreactivity was observed in vessel walls (A, B and C and enlarged boxes 1, 2 and 3). There were no significant differences in the percentage of the vessel wall positive for α1A-AR between cases (D). Graph depicts the mean ±95% confidence intervals, n = 5. Scale bar 50 µm.
Figure 4.
Immunofluorescence for α1A-AR (green) and Aβ (red) on sections of human occipital cortex of a case of CAA. The green immunofluorescence is present within the endothelium and in between the amyloid deposits of the wall of the vessel. Based on the diameter of the vessel and the thickness of the vessel wall, as well as the presence of CAA mainly in cortical arterioles, the vessels are arterioles of 10 µm diameter. Scale bar 25 µm. (A) immunostaining for Aβ occupying the whole of the vessel wall in a circumferential manner (B) immunostaining for α1A-AR showing a focal distribution; (C) the overlay image of both Aβ and α1A-AR immunofluorescence.
Figure 4.
Immunofluorescence for α1A-AR (green) and Aβ (red) on sections of human occipital cortex of a case of CAA. The green immunofluorescence is present within the endothelium and in between the amyloid deposits of the wall of the vessel. Based on the diameter of the vessel and the thickness of the vessel wall, as well as the presence of CAA mainly in cortical arterioles, the vessels are arterioles of 10 µm diameter. Scale bar 25 µm. (A) immunostaining for Aβ occupying the whole of the vessel wall in a circumferential manner (B) immunostaining for α1A-AR showing a focal distribution; (C) the overlay image of both Aβ and α1A-AR immunofluorescence.
Figure 5.
α1A-AR immunoreactivity in the vessel walls of capillaries, arteries and veins and within cultured human brain vascular smooth muscle cells. α1A-AR immunoreactivity (green) was observed colocalised (white arrows) to lectin (blue) in the vessel walls of capillaries (A–D), arteries (E–H) and veins (I–L) in all cases. α1A-AR immunoreactivity was also colocalised with smooth muscle actin (red) in arterial walls (H) and observed to outline smooth muscle cell bodies in culture (M–O). Scale bar 50 µm.
Figure 5.
α1A-AR immunoreactivity in the vessel walls of capillaries, arteries and veins and within cultured human brain vascular smooth muscle cells. α1A-AR immunoreactivity (green) was observed colocalised (white arrows) to lectin (blue) in the vessel walls of capillaries (A–D), arteries (E–H) and veins (I–L) in all cases. α1A-AR immunoreactivity was also colocalised with smooth muscle actin (red) in arterial walls (H) and observed to outline smooth muscle cell bodies in culture (M–O). Scale bar 50 µm.
Table 1.
Percentage area stained for overall and vascular specific α1A adrenergic receptor in grey, white and leptomeninges per disease state and the comparisons between disease states.
Table 1.
Percentage area stained for overall and vascular specific α1A adrenergic receptor in grey, white and leptomeninges per disease state and the comparisons between disease states.
| a | Percentage Area Stained for Overall α1A Adrenergic Receptor in… | ||||||||||||
| Grey Matter | White Matter | ||||||||||||
| Disease state | N | Mean (SD) | (Min, Max) | N | Mean (SD) | (Min, Max) | |||||||
| Young (Y) | 5 | 3.56 (1.18) | (2.68, 5.62) | 5 | 1.47 (0.47) | (1.11, 2.14) | |||||||
| Old Non-demented (O) | 5 | 2.48 (0.97) | (1.48, 3.97) | 5 | 0.79 (0.49) | (0.38, 1.48) | |||||||
| CAA (C) | 5 | 1.68 (0.71) | (0.59, 2.56) | 5 | 0.91 (0.41) | (0.39, 1.53) | |||||||
| b | Grey Matter | White Matter | |||||||||||
| Multiple Comparisons between Disease States | N | Mean Difference (95% CI) | p1 | N | Mean Difference (95% CI) | p1 | |||||||
| O–Y | 10 | −1.09 (−2.79, 0.62) | 0.305 | 10 | −0.68 (−1.49, 0.13) | 0.113 | |||||||
| C–Y | 10 | −1.88 (−3.59, −0.18) | 0.029 | 10 | −0.56 (−1.37, 0.25) | 0.233 | |||||||
| C–O | 10 | −0.79 (−2.50, 0.91) | 0.658 | 10 | 0.12 (−0.69, 0.93) | 1.000 | |||||||
| c | Percentage Area Stained for Vascular Specific α1A Adrenergic Receptor in… | ||||||||||||
| Grey Matter | White Matter | Leptomeninges | |||||||||||
| Disease State | N | Mean (SD) | (Min, Max) | N | Mean (SD) | (Min, Max) | N | Mean (SD) | (Min, Max) | ||||
| Young (Y) | 5 | 23.25 (3.33) | (17.56, 25.78) | 5 | 17.58 (9.84) | (8.84, 34.09) | 5 | 13.33 (4.21) | (6.81, 17.99) | ||||
| Old non-demented (O) | 5 | 23.22 (5.42) | (15.40, 29.40) | 5 | 15.67 (6.81) | (7.21, 21.89) | 5 | 20.82 (10.03) | (10.67, 34.60) | ||||
| CAA (C) | 5 | 18.81 (3.71) | (15.54, 24.99) | 5 | 15.72 (6.75) | (7.02, 23.12) | 5 | 13.93 (2.91) | (10.71, 18.22) | ||||
| d | Grey Matter | White Matter | Leptomeninges | ||||||||||
| Multiple Comparisons between Disease States | N | Mean Difference (95% CI) | p1 | N | Mean Difference (95% CI) | p1 | N | Mean Difference (95% CI) | p1 | ||||
| O–Y | 10 | −0.03 (−7.51, 7.44) | 1.000 | 10 | −1.91 (−15.86, 12.05) | 1.000 | 10 | 7.50 (−3.93, 18.93) | 0.280 | ||||
| C–Y | 10 | −4.44 (−11.92, 3.03) | 0.373 | 10 | −1.86 (−15.81, 12.09) | 1.000 | 10 | 0.61 (−10.82, 12.04) | 1.000 | ||||
| C–O | 10 | −4.41 (−11.88, 3.06) | 0.381 | 10 | 0.05 (−13.90, 14.00) | 1.000 | 10 | −6.89 (−18.32, 4.54) | 0.359 | ||||
1p-values are adjusted for multiple comparisons using Bonferroni correction; significance level is set at p < 0.050.
Table 2.
Demographics for the cases used.
| Source | Age | Sex | pm Delay/Hrs | Category |
|---|---|---|---|---|
| Edinburgh | 51 | M | 78 | Young |
| Edinburgh | 41 | F | 50 | Young |
| Edinburgh | 60 | M | 52 | Young |
| Edinburgh | 59 | F | 53 | Young |
| Edinburgh | 33 | M | 47 | Young |
| Newcastle | 73 | M | 25 | Old non-demented |
| Newcastle | 90 | M | 18 | Old non-demented |
| Newcastle | 95 | F | 66 | Old non-demented |
| Newcastle | 95 | M | 21 | Old non-demented |
| Newcastle | 89 | F | 98 | Old non-demented |
| Newcastle | 67 | M | 46 | CAA |
| Newcastle | 86 | F | 51 | CAA |
| Newcastle | 73 | M | 7 | CAA |
| Newcastle | 74 | F | 49 | CAA |
| Newcastle | 87 | F | 54 | CAA |
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
MDPI and ACS Style
Frost, M.; Keable, A.; Baseley, D.; Sealy, A.; Andreea Zbarcea, D.; Gatherer, M.; Yuen, H.M.; Sharp, M.M.; Weller, R.O.; Attems, J.; et al. Vascular α1A Adrenergic Receptors as a Potential Therapeutic Target for IPAD in Alzheimer’s Disease. Pharmaceuticals 2020, 13, 261. https://doi.org/10.3390/ph13090261
AMA Style
Frost M, Keable A, Baseley D, Sealy A, Andreea Zbarcea D, Gatherer M, Yuen HM, Sharp MM, Weller RO, Attems J, et al. Vascular α1A Adrenergic Receptors as a Potential Therapeutic Target for IPAD in Alzheimer’s Disease. Pharmaceuticals. 2020; 13(9):261. https://doi.org/10.3390/ph13090261
Chicago/Turabian StyleFrost, Miles, Abby Keable, Dan Baseley, Amber Sealy, Diana Andreea Zbarcea, Maureen Gatherer, Ho Ming Yuen, Matt MacGregor Sharp, Roy O. Weller, Johannes Attems, and et al. 2020. "Vascular α1A Adrenergic Receptors as a Potential Therapeutic Target for IPAD in Alzheimer’s Disease" Pharmaceuticals 13, no. 9: 261. https://doi.org/10.3390/ph13090261
APA StyleFrost, M., Keable, A., Baseley, D., Sealy, A., Andreea Zbarcea, D., Gatherer, M., Yuen, H. M., Sharp, M. M., Weller, R. O., Attems, J., Smith, C., Chiarot, P. R., & Carare, R. O. (2020). Vascular α1A Adrenergic Receptors as a Potential Therapeutic Target for IPAD in Alzheimer’s Disease. Pharmaceuticals, 13(9), 261. https://doi.org/10.3390/ph13090261
Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.
